Fenwick partner Doug Cogen has been named one of Law360’s 2024 global Life Sciences MVPs. This prestigious recognition is awarded annually to a select group of lawyers who have distinguished themselves through record-breaking deals, complex global matters, and high-stakes litigation. Doug’s selection underscores his exceptional work leading teams on several landmark deals in the life sciences sector, including Shockwave Medical’s $13.1 billion acquisition by Johnson & Johnson and Alpine Immune Sciences’ $4.9 billion acquisition by Vertex Pharmaceuticals.
In a Q&A profile with Law360, Doug reflects on how Fenwick successfully closed five major multibillion dollar MedTech and Biopharma acquisitions this past year. The profile also traces Doug's career path from architecture to M&A law, highlights his passion for team leadership and intellectual curiosity, and offers valuable advice for junior lawyers to stay adaptable and passionate about their work.
For an in-depth look at Doug's achievements and insights, read the full profile on Law360’s 2024 MVPs here.